ESMO Congress | Conferences

Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes

September 22, 2020

Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.

Survival Significantly Improved With Frontline Nivolumab Combo in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

September 21, 2020

Frontline nivolumab plus chemotherapy induced a statistically significant survival benefit compared with chemotherapy alone in patients with newly diagnosed PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma

September 21, 2020

Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.

Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 21, 2020

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

Cabozantinib Doublet Achieves Early Clinical Activity in Advanced ccRCC

September 21, 2020

Patients with advanced clear cell renal cell carcinoma treated with cabozantinib in combination with atezolizumab in the phase 1b COSMIC-021 study, had promising clinical activity, according to results from the study presented during the 2020 European Society of Medical Oncology Virtual Congress.

Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes

September 21, 2020

Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.

Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial

September 21, 2020

In patients with newly diagnosed stage III/IV ovarian cancer, adding atezolizumab to a backbone combination of bevacizumab and chemotherapy did not improve progression-free survival, missing the primary end point of the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial presented during the virtual 2020 European Society of Medical Oncology Congress.

Osimertinib Achieves Extended Disease-Free Survival in EGFR-Mutant NSCLC

September 21, 2020

In patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection, treatment with osimertinib reduced the risk for central nervous system death or progression by 82%, findings presented during the EMSO Virtual Congress 2020.

Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21, 2020

Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial.